The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Open accessAbstract
BACKGROUND: BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers. METHODS: We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort. A total of 122 patients with BRAF V600 mutation-positive cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab. The primary end point was the response rate; secondary end points included progression-free and overall survival. RESULTS: In the cohort with non-small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 months (95% CI, 3.5 to 10.8). In the cohort with Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 months (range, 0.6 to 18.6), and no patients had disease progression during therapy. There were anecdotal responses among patients with pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal cancer who received vemurafenib and cetuximab. Safety was similar to that in prior studies of vemurafenib for melanoma. CONCLUSIONS: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers. Preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis. The histologic context is an important determinant of response in BRAF V600-mutated cancers. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT01524978.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, in BRAFV600 colorectal cancer, targeting EGFR—the RTK thought to be the primary driver of feedback reactivation from preclinical studies—in combination with BRAF inhibition, has led to an improvement in clinical efficacy (34–39).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors have proven ineffective as single agents due to adaptive feedback re-activation of the MAPK and other signaling pathways [5–13, 38].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF inhibitor monotherapy is a promising treatment of many cancers, including melanoma and NSCLC; however, BRAF inhibitor efficacy in colorectal cancer patients with BRAF V600E mutations is limited (21).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast with other BRAFV600E tumors (i.e. melanoma), BRAFV600E-targeted therapy (like vemurafenib) has proven largely ineffective in CRC, with response rates <5% as single agents [5, 6].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
In the citing paper
“However, in another clinical study, CRC patients did not benefit from vemurafenib monotherapy and/or cetuximab [161].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [161]
In the citing paper
“However, a multicentric clinical study containing 27 CRC patients showed that vemurafenib alone or with cetuximab did not benefit CRC patients [99].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Research works printed but not linked: 1
- Kimura ET, 2003, Cancer Res, 63, 1454
Cited by
Sorted by citations
Items 401–500 of 1,002
Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
Grassi, E., Corbelli, J., Papiani, G., Barbera, M. A., Gazzaneo, F., & Tamberi, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.601722 · Cited by 56
Basket Trials: Review of Current Practice and Innovations for Future Trials
Hobbs, B. P., Pestana, R. C., Zabor, E. C., Kaizer, A. M., & Hong, D. S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02285 · Cited by 64
Colomer, R., Miranda, J., Romero-Laorden, N., Hornedo, J., González‐Cortijo, L., Mouron, S. A., Bueno, M. J., Mondéjar, R., & Quintela-Fandiño, M. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102029 · Cited by 57
Scientific Advances in Thoracic Oncology 2016
Soo, R. A., Stone, E. C. A., Cummings, K. M., Jett, J. R., Field, J. K., Groen, H. J. M., Mulshine, J. L., Yatabe, Y., Bubendorf, L., Đačić, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.019 · Cited by 55
Shimura, T., Tada, Y., Hirai, H., Kawakita, D., Kano, S., Tsukahara, K., Shimizu, A., Takase, S., Imanishi, Y., Ozawa, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22927 · Cited by 55
Therapeutic implications of germline genetic findings in cancer
Thavaneswaran, S., Rath, E. M., Tucker, K., Joshua, A. M., Hess, D., Pinese, M., Ballinger, M. L., & Thomas, D. M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0179-3 · Cited by 56
Precision medicine for metastatic colorectal cancer: an evolving era
Güler, İ., Aşkan, G., Klostergaard, J., & Şahin, İ. H. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1663174 · Cited by 56
Wang, V. E. H., Xue, J. Y., Frederick, D. T., Cao, Y., Lin, E., Wilson, C., Urisman, A., Carbone, D. P., Flaherty, K. T., Bernards, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2779 · Cited by 57
Clinical trial design: Past, present, and future in the context of big data and precision medicine
Li, A., & Bergan, R. C. (2020) · Cancer · doi:10.1002/cncr.33205 · Cited by 54
Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma
Sun, Y., Wang, Z., Qiu, S., & Wang, R. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.58077 · Cited by 54
Tan, L., Tran, B., Tie, J., Markman, B., Ananda, S., Tebbutt, N. C., Michael, M., Link, E. K., Wong, S. Q., Chandrashekar, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3094 · Cited by 54
DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?
Voest, E. E., & Bernards, R. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1321 · Cited by 55
Bianchi, A. S., Loupakis, F., Argilés, G., & Prager, G. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw191 · Cited by 56
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
Ermisch, M., Bucsics, A., Bonanno, P. V., Arickx, F., Bybau, A., Bochenek, T., de Casteele, M. V., Diogène, E., Fürst, J., Garuolienè, K., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00305 · Cited by 54
Brägelmann, J., Dammert, M. A., Dietlein, F., Heuckmann, J. M., Choidas, A., Böhm, S., Richters, A., Basu, D., Tischler, V., Lorenz, C., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.082 · Cited by 53
Genotype-targeted local therapy of glioma
Shankar, G. M., Kirtane, A. R., Miller, J. J., Mazdiyasni, H., Rogner, J., Tai, T., Williams, E. A., Higuchi, F., Juratli, T. A., Tateishi, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805751115 · Cited by 54
Molecular therapeutics for anaplastic thyroid cancer
Pozdeyev, N. V., Rose, M. M., Bowles, D. W., & Schweppe, R. E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.005 · Cited by 55
Chu, Q. S.-C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919895756 · Cited by 56
Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers
Maia, M. C., Salgia, M. M., & Pal, S. K. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0297-9 · Cited by 56
Targeting BRAF pathway in low-grade serous ovarian cancer
Perrone, C., Angioli, R., Luvero, D., Giannini, A., Donato, V. D., Cuccu, I., Muzii, L., Raspagliesi, F., & Bogani, G. (2024) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2024.35.e104 · Cited by 56
Sohn, A., Park, J., Kim, W., Yoon, Y., Lee, S., Ji, J., & Kim, H. (2024) · Toxics · doi:10.3390/toxics12110822 · Cited by 57
Peng, L., Wang, Y., Hong, Y. K., Ye, X., Shi, P., Zhang, J., & Zhao, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.21059 · Cited by 56
Medical Management of Cushing’s Syndrome: Current and Emerging Treatments
Hinojosa‐Amaya, J. M., Ramos, D. C., & Fleseriu, M. (2019) · Drugs · doi:10.1007/s40265-019-01128-7 · Cited by 53
Cobb, L. P., Sun, C. C., Iyer, R. B., Nick, A. M., Fleming, N. D., Westin, S. N., Sood, A. K., Wong, K., Silva, E. G., & Gershenson, D. M. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.06.498 · Cited by 53
Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches
Strickler, J. H., Wu, C. S.-Y., & Bekaii‐Saab, T. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.006 · Cited by 53
Emerging treatment options for BRAF-mutant colorectal cancer
Ursem, C. J., Atreya, C. E., & Loon, K. V. (2018) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s125940 · Cited by 54
Lengliné, É., Péron, J., Vanier, A., Gueyffier, F., Kouzan, S., Dufour, P., Guillot, B., Blondon, H., Clanet, M., Cochat, P., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00337-5 · Cited by 52
Zeng, K., Wang, Z., Ohshima, K., Liu, Y., Zhang, W., Wang, L., Fan, L., Li, M., Li, X., Wang, Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1185582 · Cited by 52
Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States
Kim, J. W., Abudayyeh, O. O., Yeerna, H., Yeang, C., Stewart, M. L., Jenkins, R. W., Kitajima, S., Konieczkowski, D. J., Medetgul-Ernar, K., Cavazos, T. B., et al. (2017) · Cell Systems · doi:10.1016/j.cels.2017.08.002 · Cited by 49
Single-agent dabrafenib for BRAF V600E -mutated histiocytosis
Bhatia, A., Ulaner, G. A., Rampal, R. K., Hyman, D. M., Abdel-Wahab, O. I., Durham, B. H., Doǧan, A., Özkaya, N., Lacouture, M. E., Hajdenberg, J. J., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.185298 · Cited by 52
Self-citationHairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment
Troussard, X., Maître, E., & Cornet, É. (2021) · American Journal of Hematology · doi:10.1002/ajh.26390 · Cited by 54
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
Majumder, A., Sandhu, M., Banerji, D., Steri, V., Olshen, A. B., & Moasser, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-88683-w · Cited by 52
Emerging Targets in Non-Small Cell Lung Cancer
Liu, L., Soler, J., Reckamp, K. L., & Sankar, K. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810046 · Cited by 58
Smith, A. L., Williams, M. D., Stewart, J., Wang, W., Krishnamurthy, S., Cabanillas, M. E., & Roy‐Chowdhuri, S. (2018) · Cancer Cytopathology · doi:10.1002/cncy.21992 · Cited by 51
Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
Chen, Y., & Chi, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0622-4 · Cited by 51
Starkebaum, G. A., & Hendrie, P. C. (2020) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2020.101510 · Cited by 55
Bertucci, F., Gonçalvès, A., Guillé, A., Adélaı̈de, J., Garnier, S., Carbuccia, N., Billon, E., Finetti, P., Sfumato, P., Monneur, A., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00897-9 · Cited by 51
Şahin, İ. H., & Klostergaard, J. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00160 · Cited by 54
Yang, J. C., & Barletta, J. A. (2020) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2020.06.005 · Cited by 50
Molecular Testing in Breast Cancer: A Guide to Current Practices
Hagemann, I. S. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0051-ra · Cited by 50
Increasing the efficiency of oncology basket trials using a Bayesian approach
Liu, R., Liu, Z., Ghadessi, M., & Vonk, R. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.06.009 · Cited by 50
Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine
Hainsworth, J. D., & Greco, F. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100014 · Cited by 50
A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology
Yip, S. S. F., Christofides, A., Banerji, S. O., Downes, M. R., Izevbaye, I., Lo, B., MacMillan, A., McCuaig, J. M., Stockley, T. L., Yousef, G. M., et al. (2019) · Current Oncology · doi:10.3747/co.26.4731 · Cited by 50
Subbiah, V., Wagner, M. J., McGuire, M. F., Sarwari, N., Devarajan, E., Lewis, V. O., Westin, S., Kato, S., Brown, R. E., & Anderson, P. M. (2015) · Oncotarget · doi:10.18632/oncotarget.5841 · Cited by 49
Self-citationEqual access to innovative therapies and precision cancer care
Buzyn, A., Blay, J., Hoog-Labouret, N., Jimenez, M., Nowak, F., Deley, M. L., Pérol, D., Cailliot, C., Raynaud, J., & Vassal, G. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.31 · Cited by 49
Self-citationHistiocytic neoplasms in the era of personalized genomic medicine
Durham, B. H., Diamond, E. L., & Abdel-Wahab, O. I. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000256 · Cited by 49
Self-citationBiological therapies in nonsmall cell lung cancer
Zugazagoitia, J., Molina‐Pinelo, S., López‐Ríos, F., & Paz-Ares, L. G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01520-2016 · Cited by 49
Remón, J., Hendriks, L. E. L., Cabrera, C., Reguart, N., & Besse, B. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.006 · Cited by 49
Precision oncology: separating the wheat from the chaff
Remón, J., & Dienstmann, R. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000446 · Cited by 49
Zheng, H., & Wason, J. M. S. (2020) · Biostatistics · doi:10.1093/biostatistics/kxaa019 · Cited by 49
Boyle, E. M., Ashby, C., Tytarenko, R. G., Deshpande, S., Wang, H., Wang, Y., Rosenthal, A., Sawyer, J. R., Tian, E., Flynt, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1507 · Cited by 50
BRAF mutation and its inhibitors in sarcoma treatment
Liu, H., Nahar, N., Hassan, S., Liu, X., & Yang, J. (2020) · Cancer Medicine · doi:10.1002/cam4.3103 · Cited by 50
Advances in the treatment of newly diagnosed glioblastoma
Theeler, B. J., & Gilbert, M. R. (2015) · BMC Medicine · doi:10.1186/s12916-015-0536-8 · Cited by 48
Hairy cell leukemia 2018: Update on diagnosis, risk‐stratification, and treatment
Troussard, X., & Cornet, É. (2017) · American Journal of Hematology · doi:10.1002/ajh.24936 · Cited by 48
Kyrochristos, I. D., & Roukos, D. H. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101894 · Cited by 49
Ortiz‐Cuaran, S., Mezquita, L., Swalduz, A., Aldea, M. D., Mazières, J., Léonce, C., Jovelet, C., Pradines, A., Avrillon, V., Flores, W. R. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1037 · Cited by 49
Self-citationSengal, A. G., Velazquez, J., Hahne, M., Burke, T. M., Abhyankar, H. A., Reyes, R., Olea, W., Scull, B., Eckstein, O. S., Bigenwald, C., et al. (2020) · Blood · doi:10.1182/blood.2020005867 · Cited by 48
Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0016-1 · Cited by 60
Personalised medicine for nonsmall cell lung cancer
Mascaux, C., Tomasini, P., Greillier, L., & Barlési, F. (2017) · European Respiratory Review · doi:10.1183/16000617.0066-2017 · Cited by 49
Malenica, I., Donadon, M., & Lleò, A. (2020) · Cancers · doi:10.3390/cancers12082190 · Cited by 48
Chen, A. P., Kummar, S., Moore, N., Rubinstein, L., Zhao, Y., Williams, P. M., Palmisano, A., Sims, D., Coyne, G. O., Rosenberger, C. L., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00372 · Cited by 47
Danesi, R., Fogli, S., Indraccolo, S., Re, M. D., Tos, A. P. D., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100040 · Cited by 52
New therapeutic opportunities for women with low-grade serous ovarian cancer
Moujaber, T., Balleine, R. L., Gao, B., Madsen, I., Harnett, P. R., & DeFazio, A. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0191 · Cited by 47
Élez, E., Kopetz, S., Tabernero, J. M., Bekaii‐Saab, T., Taı̈eb, J., Yoshino, T., Manji, G. A., Fernandez, K. C., Abbattista, A., Zhang, X., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-1249 · Cited by 47
Self-citationCetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Gonzalez, N. S., Ros, J., Baraibar, I., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · Cancers · doi:10.3390/cancers16020412 · Cited by 50
Self-citationTissue-Agnostic Drug Development
Flaherty, K. T., Le, D. T., & Lemery, S. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_173855 · Cited by 47
Kato, S., Kurasaki, K., Ikeda, S., & Kurzrock, R. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0199 · Cited by 45
Challenges with Novel Clinical Trial Designs: Master Protocols
Cecchini, M., Rubin, E. H., Blumenthal, G. M., Ayalew, K., Burris, H. A., Russell-Einhorn, M. K., Dillon, H., Lyerly, H. K., Reaman, G. H., Boerner, S. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3544 · Cited by 46
Pisapia, P., Pepe, F., Iaccarino, A., Sgariglia, R., Nacchio, M., Russo, G., Gragnano, G., Malapelle, U., & Troncone, G. (2020) · Cells · doi:10.3390/cells9122549 · Cited by 44
Cheng, W., Liu, R., Zhu, G., Wang, H., & Xing, M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3433 · Cited by 45
The Role of Next‐Generation Sequencing in Enabling Personalized Oncology Therapy
Cummings, C., Peters, E. J., Lacroix, L., André, F., & Lackner, M. (2016) · Clinical and Translational Science · doi:10.1111/cts.12429 · Cited by 47
Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy
Martínez-Gutiérrez, J. C., D’Andrea, M. R., Cahill, D. P., Santagata, S., Barker, F. G., & Brastianos, P. K. (2016) · Neurosurgical FOCUS · doi:10.3171/2016.9.focus16325 · Cited by 46
Molecular Testing of Lung Cancers
Shim, H. S., Choi, Y., Kim, L., Chang, S. H., Kim, W. S., Roh, M. S., Kim, T. J., Ha, S. Y., Chung, J.-H., Jang, S. J., et al. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.04.10 · Cited by 49
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come
Toschi, L., Rossi, S., Finocchiaro, G., & Santoro, A. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.787 · Cited by 48
Yang, Y., Wang, D., Cui, L., Ma, H., Zhang, L., Lian, H., Zhang, Q., Zhao, X., Zhang, L.-P., Zhao, Y., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.769 · Cited by 45
Mutant SF3B1 promotes AKT- and NF-κB–driven mammary tumorigenesis
Liu, B., Liu, Z., Chen, S., Ki, M., Erickson, C., Reis-Filho, J. S., Durham, B. H., Chang, Q., de Stanchina, E., Sun, Y., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138315 · Cited by 49
When the MET receptor kicks in to resist targeted therapies
Fernandes, M., Jamme, P., Cortot, A. B., Kherrouche, Z., & Tulasne, D. (2021) · Oncogene · doi:10.1038/s41388-021-01835-0 · Cited by 51
Shi, J., Chen, Y., Peng, C., Kuang, L., Zhang, Z., Li, Y., & Huang, K. (2022) · ONCOLOGIE · doi:10.32604/oncologie.2022.027545 · Cited by 45
Langerhans cell histiocytosis: current advances in molecular pathogenesis
Sconocchia, T., Foßelteder, J., Sconocchia, G., & Reinisch, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1275085 · Cited by 50
Advances in targeted therapy of cholangiocarcinoma
Li, Y., Yu, J., Zhang, Y., Peng, C., Song, Y., & Liu, S. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2310196 · Cited by 48
Universal Genomic Testing Needed to Win the War Against Cancer
Subbiah, V., & Kurzrock, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0078 · Cited by 44
Self-citationPrecision medicine in oncology: New practice models and roles for oncology pharmacists
Walko, C. M., Kiel, P. J., & Kolesar, J. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160211 · Cited by 44
Sheikine, Y., Pavlick, D. C., Klempner, S. J., Trabucco, S. E., Chung, J., Rosenzweig, M. R., Wang, K., Velcheti, V., Frampton, G. M., Peled, N., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00172 · Cited by 46
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Hierro, C., Matos, I. G., Martín-Liberal, J., de Olza, M. O., & Garralda, E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3694 · Cited by 44
Shatsky, R. A., Parker, B. A., Bui, N. Q., Helsten, T. L., Schwab, R. B., Boles, S. G., & Kurzrock, R. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1038 · Cited by 44
Molecular Profiling–Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges
Zhang, Q., Fu, Q., Bai, X., & Liang, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.532403 · Cited by 46
Braga, D., Barcella, M., Herpain, A., Aletti, F. M., Kistler, E. B., Pinto, B. B., Bendjelid, K., & Barlassina, C. (2019) · Critical Care · doi:10.1186/s13054-019-2670-8 · Cited by 43
New Directions in the Treatment of Glioblastoma
Reitman, Z. J., Winkler, F., & Elia, A. E. H. (2018) · Seminars in Neurology · doi:10.1055/s-0038-1623534 · Cited by 45
Furuta, T., Miyoshi, H., Komaki, S., Arakawa, F., Morioka, M., Ohshima, K., Nakada, M., & Sugita, Y. (2018) · Neuropathology · doi:10.1111/neup.12459 · Cited by 43
A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer
Ljubas, J., Ovesen, T., & Rusan, M. (2019) · Cancers · doi:10.3390/cancers11070943 · Cited by 43
Update on Pulmonary Langerhans Cell Histiocytosis
Radzikowska, E. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.582581 · Cited by 43
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Aleksakhina, S. N., & Imyanitov, E. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010931 · Cited by 41
Valéry, M., Vasseur, D., Fachinetti, F., Boilève, A., Smolenschi, C., Tarabay, A., Antoun, L., Perret, A., Fuerea, A. C., Pudlarz, T., et al. (2023) · Cancers · doi:10.3390/cancers15184446 · Cited by 44
Self-citationAdamopoulos, C., Cave, D. D., & Papavassiliou, A. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031631 · Cited by 43
Lerner, S. P., Bajorin, D. F., Dinney, C. P., Efstathiou, J. A., Groshen, S. G., Hahn, N. M., Hansel, D. E., Kwiatkowski, D. J., O’Donnell, M. A., Rosenberg, J. E., et al. (2016) · Bladder Cancer · doi:10.3233/blc-160053 · Cited by 42
Variance prior specification for a basket trial design using Bayesian hierarchical modeling
Cunanan, K. M., Iasonos, A. E., Shen, R., & Gönen, M. (2018) · Clinical Trials · doi:10.1177/1740774518812779 · Cited by 41
Tumor-Agnostic Drug Development
Offin, M. D., Liu, D., & Drilon, A. E. D. C. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200831 · Cited by 42
Béal, J., Pantolini, L., Noël, V., Barillot, E., & Calzone, L. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007900 · Cited by 47
Xu, Q., Wang, C., Zhou, J., Xu, Z.-M., Gao, J., Sui, P., Walsh, C. P., Ji, H., & Xu, G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107599119 · Cited by 41
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
Adashek, J. J., Menta, A. K., Reddy, N. K., Desai, A. P., Roszik, J., & Subbiah, V. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0950 · Cited by 42
Self-citation
Metadata
- Authors
- Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., Gervais, R., Elez-Fernandez, M. E., Italiano, A., Hofheinz, R.-D., Hidalgo, M., Chan, E., Schuler, M., Lasserre, S. F., Makrutzki, M., Sirzen, F., Veronese, M. L., Tabernero, J., & Baselga, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut...
- F. Hoffmann-La Roche AG (CH)
- Universitat Autònoma de Barcelona (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-20
- Volume
- 373
- Issue
- 8
- Pages
- 726-736
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4971773
- OpenAlex
- W1846586690
- Semantic Scholar
- abd7e5ae4940f84d6af08e479e67fa7e4788098c
- Cited by
- 1,764
- References
- 31
- Citations by year
- 2026: 55 · 2025: 102 · 2024: 115 · 2023: 122 · 2022: 143 · 2021: 189 · 2020: 210 · 2019: 192 · 2018: 192 · 2017: 241 · 2016: 169 · 2015: 30
- FWCI
- 91.52
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-10-18)
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, basket trials, non-small cell lung cancer, Erdheim-Chester disease, Langerhans cell histiocytosis, colorectal cancer, cetuximab, pleomorphic xanthoastrocytoma, anaplastic thyroid carcinoma, cholangiocarcinoma, ovarian cancer, clear cell sarcoma, targeted therapy
- MeSH terms
- Vemurafenib, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasms, Sulfonamides, Histiocytosis, Disease-Free Survival, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
